Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 1034 record(s)

Req # A-2020-000409

Adverse Reaction Reports (AERs). Report numbers: E2B_03042685, E2B_03043235, E2B_03043502, E2B_03046113.

Organization: Health Canada

62 page(s)
November 2020

Req # A-2020-000412

Adverse Reaction Reports (AERs). Report numbers: E2B_03048477, E2B_03048789.

Organization: Health Canada

50 page(s)
November 2020

Req # A-2020-000413

Adverse Reaction Reports (AERs). Report numbers: E2B_03028565, E2B_03028567, E2B_03028605, E2B_03028607.

Organization: Health Canada

74 page(s)
November 2020

Req # A-2020-000461

Adverse Reaction Report (AER) for Pms-Epirubicin. Report number: E2B_02763034.

Organization: Health Canada

15 page(s)
November 2020

Req # A-2020-000613

Adverse Reaction Reports (AERs). Report numbers: E2B_03133267, E2B_03150308.

Organization: Health Canada

38 page(s)
November 2020

Req # A-2020-000720

Adverse Reaction Reports (AERs) for Mesalazine. Report numbers: E2B_03143352, E2B_03149455, E2B_03154815, E2B_03166561, E2B_03166583, E2B_03169169 , E2B_03169172 , E2B_03170001. AER for Antihemophilic factor (recombinant). Report number: E2B_03002376.

Organization: Health Canada

86 page(s)
November 2020

Req # A-2020-000818

Adverse Reaction Report (AER) for Botulinum toxin. Report number: E2B_03232927.

Organization: Health Canada

10 page(s)
November 2020

Req # A-2020-000882

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: #20-103762-537, Public release of vaping results from the Canadian Tobacco and Nicotine Survey (2019) on March 5, 2020.

Organization: Health Canada

31 page(s)
November 2020

Req # A-2020-000891

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-108854-87, Memo to DM Privacy Policy Instrument for COVID-19 Initiatives.

Organization: Health Canada

67 page(s)
November 2020

Req # A-2020-000986

Adverse Reaction Report (AER) for Prevegyne® (ascorbic acid). Report number: 000563334.

Organization: Health Canada

25 page(s)
November 2020
Date modified: